Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6942MR)

This product GTTS-WQ6942MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6942MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9564MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ11736MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ12767MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ6726MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ6094MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ11693MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15396MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ5970MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW